Global trends in clinical trials and interventions for the metabolic syndrome: A comprehensive analysis of the WHO International Clinical Trials platform

被引:1
作者
Muvhulawa, Ndivhuwo [1 ,2 ]
Dludla, Phiwayinkosi, V [1 ,3 ]
Ndlovu, Musawenkosi [1 ]
Ntamo, Yonela [1 ]
Mayeye, Asanda [1 ]
Luphondo, Nomahlubi [1 ]
Hlengwa, Nokulunga [3 ]
Basson, Albertus K. [3 ]
Mabhida, Sihle E. [4 ]
Hanser, Sidney [5 ]
Mazibuko-Mbeje, Sithandiwe E. [2 ]
Nkambule, Bongani B. [6 ]
Ndwandwe, Duduzile [1 ]
机构
[1] South African Med Res Council, Cochrane South Africa, POB 19070, ZA-7505 Tygerberg, South Africa
[2] North West Univ, Dept Biochem, Mafikeng Campus, ZA-2735 Mmabatho, South Africa
[3] Univ Zululand, Dept Biochem & Microbiol, ZA-3886 Kwa Dlangezwa, South Africa
[4] South African Med Res Council, Noncommunicable Dis Res Unit, ZA-7505 Tygerberg, South Africa
[5] Univ Limpopo, Dept Physiol & Environm Hlth, ZA-0727 Sovenga, South Africa
[6] Univ KwaZulu Natal, Sch Lab Med & Med Sci, ZA-4000 Durban, South Africa
基金
英国医学研究理事会;
关键词
Metabolic syndrome; Global trends; International Clinical Trials Registry Platform; (ICTRP); Demographic characteristics; Treatment modalities; CARDIOVASCULAR-DISEASE; RISK-FACTORS; DIET;
D O I
10.1016/j.conctc.2024.101330
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Metabolic syndrome has emerged as a significant global public health concern, necessitating comprehensive examination alongside cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2D). This study provides a comprehensive analysis of clinical trials, drawing upon data sourced from the International Clinical Trials Registry Platform (ICTRP), until April 2023. Information pertaining to trial attributes and intervention features was gathered and subsequently summarized. Among the 2379 studies found on ICTRP from 18 clinical registries, ClinicalTrials.gov was the most popular with 55 % of the studies, based on data emerging from the United States. Most trials were for treatment (44 %) and prevention (17 %), with fewer focused on basic science, and diagnostic purposes. Diet and exercise were the most prominent, with 710 and 247 studies, respectively. Metformin and statins emerge as leading pharmacological therapies, reflecting the prevalence of CVD and T2D in the context of metabolic syndrome. However, there is growing recognition of other promising interventions, such as GlucagonLike Peptide-1 agonists and Dipeptidyl Peptidase IV inhibitors, which offer potential in slowing the progression of metabolic syndrome-related conditions. Notably, clinical trials primarily assessed diagnostic markers like lipid profiles, insulin, and blood pressure, rather than body mass and body mass index. These parameters are crucial for evaluating the effectiveness and safety of interventions for metabolic syndrome due to its multi-condition nature. Most studies aimed to address general symptom relief, while highlighting a need for additional welldesigned treatment trials with rigorous methodologies in accordance with the World Health Organization's guidance for consistent evaluation and treatment.
引用
收藏
页数:10
相关论文
共 46 条
[1]  
Ahmed M, 2022, J DIABETES METAB DIS, V21, P1011, DOI 10.1007/s40200-021-00965-2
[2]  
[Anonymous], WHO guidelines
[3]  
Boutari Chrysoula, 2022, Metabolism, V133, P155217, DOI 10.1016/j.metabol.2022.155217
[4]   Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome [J].
Bouzas, Cristina ;
Pastor, Rosario ;
Garcia, Silvia ;
Monserrat-Mesquida, Margalida ;
Martinez-Gonzalez., Miguel Angel ;
Salas-Salvado, Jordi ;
Corella, Dolores ;
Goday, Albert ;
Martinez, J. Alfredo ;
Alonso-Gomez, Angel M. ;
Fernandez-Barcelo, Olga ;
Vioque, Jesus ;
Romaguera, Dora ;
Lopez-Miranda, Jose ;
Estruch, Ramon ;
Tinahones, Francisco J. ;
Lapetra, Jose ;
Serra-Majema, Lluis ;
Riquelme-Gallegop, Blanca ;
Martin-Sanchez, Vicente ;
Pinto, Xavier ;
Delgado-Rodriguez, Miguel ;
Matia, Pilar ;
Vidal, Josep ;
Cardenas-Salas, Jersy-Jair ;
Daimiel, Lidia ;
Ros, Emilio ;
Toledo, Estefania ;
Manzanares, Josep M. ;
Gonzalez-Monge, Inmaculada ;
Munoz, Miguel-Angel ;
Martinez-Urbistondo, Diego ;
Tojal-Sierra, Lucas ;
Munoz-Bravoaf, Carlos ;
Miralles-Gisbert, Salvador ;
Martin, Marian ;
Garcia-Rios, Antonio ;
Castro-Barquero, Sara ;
Fernandez-Garcia, Jose Carlos ;
Santos-Lozano, Jose Manuel ;
Basterra-Gortari, F. Javier ;
Gutierrez-Carrasquilla, Liliana ;
Guillem-Saiz, Patricia ;
Satorres, Alba ;
Abete, Itziar ;
Sorto-Sanchez, Carolina ;
Diez-Espino, Javier ;
Babio, Nancy ;
Fito, Montse ;
Tur, Josep A. .
BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
[5]   Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis [J].
Bowo-Ngandji, Arnol ;
Kenmoe, Sebastien ;
Ebogo-Belobo, Jean Thierry ;
Kenfack-Momo, Raoul ;
Takuissu, Guy Roussel ;
Kengne-Nde, Cyprien ;
Mbaga, Donatien Serge ;
Tchatchouang, Serges ;
Kenfack-Zanguim, Josiane ;
Lontuo Fogang, Robertine ;
Zeuko'o Menkem, Elisabeth ;
Ndzie Ondigui, Juliette Laure ;
Kame-Ngasse, Ginette Irma ;
Magoudjou-Pekam, Jeannette Nina ;
Wandji Nguedjo, Maxwell ;
Assam Assam, Jean Paul ;
Enyegue Mandob, Damaris ;
Ngondi, Judith Laure .
PLOS ONE, 2023, 18 (07)
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]   Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials [J].
Dludla, Phiwayinkosi, V ;
Nkambule, Bongani B. ;
Mazibuko-Mbeje, Sithandiwe E. ;
Nyambuya, Tawanda M. ;
Mxinwa, Vuyolwethu ;
Mokgalaboni, Kabelo ;
Ziqubu, Khanyisani ;
Cirilli, Ilenia ;
Marcheggiani, Fabio ;
Louw, Johan ;
Tiano, Luca .
PHARMACOLOGICAL RESEARCH, 2021, 163
[8]   Metformin and heart failure-related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials [J].
Dludla, Phiwayinkosi, V ;
Nyambuya, Tawanda M. ;
Johnson, Rabia ;
Silvestri, Sonia ;
Orlando, Patrick ;
Mazibuko-Mbeje, Sithandiwe E. ;
Gabuza, Kwazi B. ;
Mxinwa, Vuyolwethu ;
Mokgalaboni, Kabelo ;
Tiano, Luca ;
Muller, Christo J. F. ;
Louw, Johan ;
Nkambule, Bongani B. .
HEART FAILURE REVIEWS, 2021, 26 (06) :1437-1445
[9]   Metabolic syndrome - a new definition and management guidelines [J].
Dobrowolski, Piotr ;
Prejbisz, Aleksander ;
Kurylowicz, Alina ;
Baska, Alicja ;
Burchardt, Pawel ;
Chlebus, Krzysztof ;
Dzida, Grzegorz ;
Jankowski, Piotr ;
Jaroszewicz, Jerzy ;
Jaworski, Pawel ;
Kaminski, Karol ;
Kaplon-Cieslicka, Agnieszka ;
Klocek, Marek ;
Kukla, Michal ;
Mamcarz, Artur ;
Mastalerz-Migas, Agnieszka ;
Narkiewicz, Krzysztof ;
Ostrowska, Lucyna ;
Sliz, Daniel ;
Tarnowski, Wieslaw ;
Wolf, Jacek ;
Wylezol, Mariusz ;
Zdrojewski, Tomasz ;
Banach, Maciej ;
Januszewicz, Andrzej ;
Bogdanski, Pawel .
ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (05) :1133-1156
[10]   TREATMENT BENEFITS ON METABOLIC SYNDROME WITH DIET AND PHYSICAL ACTIVITY [J].
Dragusha, Gani ;
Elezi, Abdulla ;
Dragusha, Shpend ;
Gorani, Daut ;
Begolli, Luljeta ;
Saiti, Valton .
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2010, 10 (02) :169-176